SSC
IKT icon

Spruce Street Capital’s Inhibikase Therapeutics IKT Stock Holding History

Spruce Street Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.27M Hold
3,581,603
– – 1.43% 21
2026
Q1 		$6.02M Hold
3,581,603
– – 1.45% 21
2025
Q4 		$7.34M Buy
+3,581,603
New +$5.7M 2.43% 14

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Spruce Street Capital's IKT Position: Q2 2026 in Review

Spruce Street Capital held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 3,581,603 shares worth $7.27M. The position accounts for 1.43% of the portfolio, ranked #21.

Spruce Street Capital first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.34M in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Spruce Street Capital held 3,581,603 shares of Inhibikase Therapeutics worth $7.27M as of Q2 2026.
  • Spruce Street Capital left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up 1.43% of Spruce Street Capital's portfolio in Q2 2026, its #21 holding.
  • Spruce Street Capital first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Spruce Street Capital's Inhibikase Therapeutics position peaked at $7.34M in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.